Background: In recent times Glycated Albumin routinely using as glycemic parameter to asses the status of diabetes complications. Type 2 diabetes mainly due to shortage or scarcity of insulin secretion. This insulin secretion again influenced by many factors and enzymes in our body, one such enzyme is Adenosine Deaminase (ADA). So far there are very limited studies available to explore the clinical correlation between glycated products such as Glycated Albumin with ADA in type 2 diabetes mellitus (Type 2 DM).

Material and Methods: In this case control study, all the subjects included were divided into 3 groups. Group A consisted of 80 normal healthy individuals who served as controls with no history of DM. Group B consisted of 80 patients of Type 2 DM both males & females in the age group of 45-70 years on oral hypoglycaemic drugs with GA<18%. Group C consisted of 60 patients of Type 2 diabetes mellitus both males & females in the age group of 45-70 years on oral hypoglycaemic drugs with GA>18%. serum levels of fasting blood sugar, glycated albumin, HbA1c, ADA and uric acid were estimated in all the subjects.

Results: All the three parameters, FBS, GA, HbA1cand ADA levels were found to be increased in the patients of Type 2 DM as compared to controls.

Conclusion: From the Present Study, It Is Concluded That There Is an Increase In Serum ADA Levels With Increase In GA levels.

Keywords: Glycated Albumin (GA), HbA1_c, adenosine Deaminase, (ADA), Fasting Blood Glucose (FBG), Type 2 Diabetes Mellitus (T2DM).

1. Nathan DM, DCCT/EDIC Research Group (2014) The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 37: 9-16.
2. Bobb A, Gale D, Manmohan S, Mohammed A, Seetahal F, et al. (2008) The impact of the chronic disease assistance plan (CDAP) on the control of type 2 diabetes in Trinidad. Diabetes Res Clin Pract 80: 360-364.
3. Havilah P, Vinodh BP, Prasad KD (2013) Adenosine deaminase activity in type-2 diabetes mellitus-An independent marker of glycemic status and stimulator of lipid peroxidation. Int J Chem Life Sci 2: 1175-1178.
4. Kouzu H, Miki T, Tanno M, Kuno A, Yano T, et al. (2015) Excessive degradation of adenine nucleotides by up-regulated AMP deaminase underlies afterload- induced diastolic dysfunction in the type 2 diabetic heart. J Mol Cell Cardiol .136-145 :80
5. Admyre T, Amrot-Fors L, Andersson M, Bauer M, Bjursell M, et al. (2014) Inhibition of AMP deaminase activity does not improve glucose control in rodent models of insulin resistance or diabetes. Chem Biol 21: 1486-1496.
6. Thakur M, Javarappa D (2014) Adenosine deaminase and malondialdehyde ‏.14 levels in type-2 diabetes mellitus-a short study. Glob J Med Res
7. Zhang W, Wang J, Wang H, Tang R, Belcher JD, et al. (2010) Adenosine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/Akt signaling pathway. Arterioscler Thromb Vasc ‏.1000-1006 :30Biol
8. Khemka VK, Bagchi D, Ghosh A, Sen O, Bir A, et al. (2013) Raised serum adenosine deaminase level in nonobese type 2 diabetes mellitus. Scienti c ‏.404320: World Journal.

9. Hoshino T, Yamada K, Masuoka K, et al. Elevated adenosine deamin- ase activity in the serum of patients with DM. Diabetes Res ClinPract1994; 25: 97-102.
10. Kondaveeti SB, Kumaraswamy D, Mishra S, et al. Evaluation of glycated albumin and microalbuminuria as early risk markers of nephropathy in type 2 diabetes mellitus. J Clin Diagnostic Res [Internet]. 2013 Jul [cited 2014 Jul 2];7:1280-1283. Available from: http:// www.jcdr.net // back_issues.asp.
11. Kondaveeti SB, et al. Glycated albumin and microalbuminuria as risk factors in diabetic retinopathy of type 2 diabetes patients. J Scientific Biological Opinion 2013;1:1-4.
12. Kondaveeti SB, et al. Evaluation of glycated albumin and dyslipidemia in type 2 diabetes mellitus. Int J Bioassays 2012;1:112-115.
13. Santigo JV, Davis JE and Fisher F. Haemoglobin A1c levels in diabetic detec-tion. J ClinEndocrinol1978; 47: 578-81.
14. Stymvoli M, Goldstecn B, Haeften TW. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 2005; 365: 1333-45.
15. Bona KS, Belle LP, Sari MH, Thome G, Schetinger MRC, Morsch VM, et al. Syzygiumcumini extract decrease Adenosine deaminase, 5’ nucleotidase activities and oxidative damage in platelets of diabetic patients. Cell Physio lBiochem2010; 26: 729-38.
16. Kurtul N, Pence S, Akarsu E, et al. Adenosine deaminase activity in the serum of type 2 diabetic patients. Acta Medica (Hradec Kralove) 2004; 47 (1): 33-35.
17. Kumar V, Abbas AK, Fausto N. The endocrine system. Robbins and Cotran Pathologic basis of disease 7th ed; 2008. p. 1198.
18. Ahmed N. Advanced glycation end products role in pathology of diabetic complications. Diab Res ClinPract2005; 67: 3-21.
19. Dehghan A, Van Hoek M, Sijbrands EJG, Hofman A, and Witteman JCM. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008; 31: 361–62.
20. Modan M, Halkin H, Karasik A and Lusky A. Elevated serum uric acid – a facet of hyperinsulinaemia. Diabetologia1987; 30: 713-18.

Dr Suresh Babu Kondaveeti

Associate Professor, Department of Biochemistry

NIMS University, Jaipur, Rajasthan, INDIA

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.